TY - JOUR AU - Yu, Jia AU - Qin, Bo AU - Moyer, Ann M. AU - Sinnwell, Jason P. AU - Thompson, Kevin J. AU - Copland, John A. AU - Marlow, Laura A. AU - Miller, James L. AU - Yin, Ping AU - Gao, Bowen AU - Minter-Dykhouse, Katherine AU - Tang, Xiaojia AU - McLaughlin, Sarah A. AU - Moreno-Aspitia, Alvaro AU - Schweitzer, Anthony AU - Lu, Yan AU - Hubbard, Jason AU - Northfelt, Donald W. AU - Gray, Richard J. AU - Hunt, Katie AU - Conners, Amy L. AU - Suman, Vera J. AU - Kalari, Krishna R. AU - Ingle, James N. AU - Lou, Zhenkun AU - Visscher, Daniel W. AU - Weinshilboum, Richard AU - Boughey, Judy C. AU - Goetz, Matthew P. AU - Wang, Liewei PY - 2017 DA - 2017/12/06 TI - Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study JO - Breast Cancer Research SP - 130 VL - 19 IS - 1 AB - Patient-derived xenografts (PDXs) are increasingly used in cancer research as a tool to inform cancer biology and drug response. Most available breast cancer PDXs have been generated in the metastatic setting. However, in the setting of operable breast cancer, PDX models both sensitive and resistant to chemotherapy are needed for drug development and prospective data are lacking regarding the clinical and molecular characteristics associated with PDX take rate in this setting. SN - 1465-542X UR - https://doi.org/10.1186/s13058-017-0920-8 DO - 10.1186/s13058-017-0920-8 ID - Yu2017 ER -